News articles about Juniper Pharmaceuticals (NASDAQ:JNP) have trended somewhat positive on Monday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Juniper Pharmaceuticals earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 44.5476687251395 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of equities analysts have weighed in on JNP shares. HC Wainwright reiterated a “neutral” rating on shares of Juniper Pharmaceuticals in a research report on Monday, November 6th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.
Juniper Pharmaceuticals (JNP) traded up $0.05 on Monday, hitting $4.70. 6,600 shares of the company’s stock were exchanged, compared to its average volume of 31,609. The company has a market capitalization of $50.42, a price-to-earnings ratio of 7.97 and a beta of 0.03. Juniper Pharmaceuticals has a fifty-two week low of $3.65 and a fifty-two week high of $6.10. The company has a current ratio of 2.00, a quick ratio of 1.68 and a debt-to-equity ratio of 0.08.
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.